Gouverneur, Amandine http://orcid.org/0000-0001-6253-1833
Avouac, Jérôme http://orcid.org/0000-0002-2463-218X
Prati, Clément
Cracowski, Jean-Luc http://orcid.org/0000-0003-0787-1469
Schaeverbeke, Thierry
Pariente, Antoine http://orcid.org/0000-0002-7873-5483
Truchetet, Marie-Elise
Article History
Received: 14 July 2022
Accepted: 7 October 2022
First Online: 26 October 2022
Declarations
:
: The study protocol was approved by the <i>Comité d’expertise pour les recherches, les études et les évaluations dans le domaine de la santé</i> (CERESS) and the <i>Commission Nationale de l’Informatique et des Libertés</i> (CNIL).
: No informed consent was needed for the use of this anonymized healthcare database or anonymized pharmacovigilance database.
: All authors have completed the ICMJE uniform disclosure form at ExternalRef removed and declare: Amandine Gouverneur, Clément Prati, and Jean-Luc Cracowski no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work; no support from any organization for the submitted work; Antoine Pariente reports acting as an independent expert towards the French Medicines Agency (<i>Agence Nationale de Securité du Médicament et des Produits de Santé, ANSM</i>) and the European Medicines Agency (EMA). Antoine Pariente coordinates the DRUGS Systematized Assessment in real-liFe EnviRonment (DRUGS-SAFER) program funded by the <i>Agence Nationale de Sécurité du Médicament et des Produits de Santé</i> (ANSM); Jérôme Avouac has/had consultancy relationship and/or research funding in the area of potential treatments for rheumatoid arthritis from (last three years): Abbvie, Galapagos, Pfizer, Bristol Myers Squibb, Sanofi, Nordic Pharma, Chugai, and MSD; Thierry Schaeverbeke has/had consultancy and/or research fundings: Abbvie, Lilly, Pfizer, Galapagos, Novartis, BMS, Medac, NordicPharma, Biogen, Mylan, Janssen; Marie-Elise Truchetet has/had consultancy relationship and/or research funding in the area of potential treatments for rheumatoid arthritis and spondyloarthritis and their complications from (last three years): Abbvie, Galapagos, Lilly, Medac, Novartis, Pfizer, and Roche; no other relationships or activities that could appear to have influenced the submitted work.